Scaling back treatment for three kinds of cancer can make life easier for patients without compromising outcomes, doctors reported at the world鈥檚 largest cancer conference.
It鈥檚 part of a long-term trend toward studying whether doing less 鈥� , or 鈥� can help patients live longer and feel better. The latest studies involved ovarian and esophageal cancer and Hodgkin lymphoma.
Thirty years ago, cancer research was about doing more, not less. In one sobering example, women with advanced breast cancer were pushed to the brink of death with massive doses of chemotherapy and bone marrow transplants. The any better than chemotherapy and patients suffered.
Now, in a quest to optimize cancer care, researchers are asking: 鈥淒o we need all that treatment that we have used in the past?鈥�
It鈥檚 a question, 鈥渢hat should be asked over and over again,鈥� said Dr. Tatjana Kolevska, medical director for the Kaiser Permanente National Cancer Excellence Program, who was not involved in the new research.
Often, doing less works because of improved drugs.
鈥淭he good news is that cancer treatment is not only becoming more effective, it鈥檚 becoming easier to tolerate and associated with less short-term and long-term complications,鈥� said Dr. William G. Nelson of Johns Hopkins School of Medicine, who was also not involved in the new research.
Studies demonstrating the trend were discussed over the weekend at an American Society of Clinical Oncology conference in Chicago. Here are the highlights:
OVARIAN CANCER
French researchers found that it鈥檚 safe to avoid removing lymph nodes that appear healthy during surgery for advanced ovarian cancer. The study compared the results for 379 patients 鈥� half had their lymph nodes removed and half did not. After nine years, there was no difference in how long the patients lived and those with less-extreme surgery had fewer complications, such as the need for blood transfusions. The research was funded by the National Institute of Cancer in France.
ESOPHAGEAL CANCER
This German study looked at 438 people with a type of cancer of the esophagus that can be treated with surgery. Half received a common treatment plan that included chemotherapy and surgery on the esophagus, the tube that carries food from the throat to the stomach. Half got another approach that includes radiation too. Both techniques are considered standard. Which one patients get can depend on where they get treatment.
After three years, 57% of those who got chemo and surgery were alive, compared to 51% of those who got chemo, surgery and radiation. The German Research Foundation funded the study.
HODGKIN LYMPHOMA
A comparison of two chemotherapy regimens for advanced Hodgkin lymphoma found the less intensive treatment was more effective for the blood cancer and caused fewer side effects.
After four years, the less harsh chemo kept the disease in check in 94% of people, compared to 91% of those who had the more intense treatment. The trial included 1,482 people in nine countries 鈥� Germany, Austria, Switzerland, the Netherlands, Denmark, Sweden, Norway, Australia and New Zealand 鈥� and was funded by Takeda Oncology, the maker of one of the drugs used in the gentler chemo that was studied.
